On 30 June 2026, Guangdong True Health Medical Tech Dev Co., Ltd. (TH Medical, 2697.HK) successfully listed on the Main Board of the Hong Kong Stock Exchange (HKEx), raising a total of approximately HKD 450 million. CBI is honored to participate in the due diligence work for this IPO Project.

Guangdong True Health Medical Tech Dev Co., Ltd. is primarily engaged in the development and commercialization of percutaneous puncture and ablation surgical robots in China. The company's core products are percutaneous puncture surgical robots, including four models: TH-S1, TH-S, TH-S Pro, and TH-SA.

In this IPO project, CBI primarily assisted the sponsor team in conducting due diligence on the company group, its directors, senior management, shareholders, customers and suppliers, etc. In addition to the basic information such as litigation, bankruptcy, winding-up and media records, CBI also assisted the sponsor team in conducting ultimate beneficial owner search, reputation intelligence and related company search. The due diligence project globally covered 3 countries and regions, including China, Hong Kong and Macau.